Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy

Glob Reg Health Technol Assess. 2022 Feb 17:9:30. doi: 10.33393/grhta.2022.2383. eCollection 2022 Jan-Dec.
No abstract available